Condition

Stage 4 NSCLC

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting2

Common interventions8

Lead sponsors shown3

Clinical trials

3 shown

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.NCT07365319 · 2026-06-15

RECRUITING

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the ThoraxNCT06262321 · 2024-05-15

RECRUITING

Universal Immunization to Fortify Immunotherapy Efficacy and ResponseNCT07597070 · 2026-11-01

NOT_YET_RECRUITING

Common interventions

EIK1001DRUG1 Nab-paclitaxel + CarboplatinDRUG1 Paclitaxel + CarboplatinDRUG1 Pembrolizumab (KEYTRUDA®)DRUG1 Pemetrexed + Cisplatin /CarboplatinDRUG1 Pfizer-BioNTech mRNA COVID-19 vaccineBIOLOGICAL1 PlaceboDRUG1 Prophylactic Palliative RadiotherapyRADIATION1

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

placebo1

Leading sponsors

Eikon Therapeutics 1 University of Florida 1 University of Rochester 1

Trial status mix

RECRUITING2

NOT_YET_RECRUITING1

Phase mix

PHASE23

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.